aTyr Pharma Inc (LIFE)
2.00
+0.07
(+3.63%)
USD |
NASDAQ |
May 17, 16:00
2.00
0.00 (0.00%)
After-Hours: 20:00
aTyr Pharma Research and Development Expense (Annual): 42.29M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 42.29M |
| December 31, 2022 | 42.81M |
| December 31, 2021 | 23.26M |
| December 31, 2020 | 17.29M |
| December 31, 2019 | 14.05M |
| December 31, 2018 | 20.38M |
| Date | Value |
|---|---|
| December 31, 2017 | 30.07M |
| December 31, 2016 | 42.85M |
| December 31, 2015 | 34.50M |
| December 31, 2014 | 16.78M |
| December 31, 2013 | 13.83M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
14.05M
Minimum
2019
42.81M
Maximum
2022
27.94M
Average
23.26M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Vaxart Inc | 68.14M |
| Allogene Therapeutics Inc | 242.91M |
| AIM ImmunoTech Inc | 10.94M |
| Protalix BioTherapeutics Inc | 17.09M |
| Armata Pharmaceuticals Inc | 33.77M |